Kyle MacBeth
25Patents
6h-index
48Co-inventors
69Inventor score
Filing activity: Nov 14, 1997 → Jul 2, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6300092A | Methods of use of a novel lysyl oxidase-related protein | Human Necessities | 20 | Expired |
| US9499514B2 | Antiproliferative compounds and methods of use thereof | Chemistry; Metallurgy | 19 | Active |
| US6872811B1 | HRPCa9 and HRPCa10 nucleic acids and polypeptides | Chemistry; Metallurgy | 18 | Expired |
| US7301016B2 | Human transferase family members and uses thereof | Chemistry; Metallurgy | 10 | Expired |
| US9808451B2 | Antiproliferative compounds and methods of use thereof | Chemistry; Metallurgy | 9 | Active |
| US5932422A | Modulation of drug resistance via ubiquitin carboxy-terminal hydrolase | Human Necessities | 7 | Expired |
| US9968596B2 | Antiproliferative compounds and methods of use thereof | Chemistry; Metallurgy | 6 | Active |
| US10695352B2 | Combination therapy for treating malignancies | Human Necessities | 4 | Active |
| US10245258B2 | Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide | Human Necessities | 4 | Active |
| US8841277B2 | Methods for treating non-small cell lung cancer using 5-azacytidine | Human Necessities | 4 | Active |
| US7485308B2 | 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206, and 8843 molecules and uses therefor | Emerging Cross-Sectional Technologies | 3 | Active |
| US10996215B2 | Methods for determining drug efficacy for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancers | Physics | 3 | Active |
| US9125884B2 | Methods for treating cancers using oral formulations of cytidine analogs | Human Necessities | 2 | Active |
| US10653710B2 | Combination therapy for treating malignancies | Human Necessities | 2 | Active |
| US11241423B2 | Antiproliferative compounds and methods of use thereof | Chemistry; Metallurgy | 1 | Active |
| US7098015B2 | 27875, 22025, 27420, 17906, 16319, 55092 and 10218 molecules and uses therefor | Physics | 1 | Expired |
| US9693987B2 | Methods for treating cancers using oral formulations of cytidine analogs | Human Necessities | 1 | Active |
| US7071004B1 | 14094, a novel human trypsin family member and uses thereof | Physics | 1 | Expired |
| US6322982A | Modulation of drug resistance via ubiquitin carboxy-terminal hydrolase | Human Necessities | 0 | Expired |
| US9101579B2 | Inhibition of drug resistant cancer cells | Human Necessities | 0 | Active |
| US6369210B1 | 22012, human carboxypeptidase | Chemistry; Metallurgy | 0 | Expired |
| US8492361B2 | Methods for treating non-small cell lung cancer using 5-azacytidine | Human Necessities | 0 | Active |
| US11590117B2 | Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide | Human Necessities | 0 | Active |
| US7235634B2 | 2786, a novel human aminopeptidase | Human Necessities | 0 | Expired |
| US6383780B1 | 2786, a novel human aminopeptidase | Human Necessities | 0 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.